



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

JAN 22 2001

Food and Drug Administration
2098 Gaither Road
Rockville MD 20850

Ms. Liane F. Gossett, MT (ASCP), SI
Manager, Quality Assurance
MedTek Diagnostics, LLC
P.O. Box 14125
Research Triangle Park, North Carolina 27709-4125

Re: K002930
Trade Name: Instaccult™ Fecal Occult Blood Test
Regulatory Class: II
Product Code: KHE
Dated: November 21, 2000
Received: November 22, 2000

Dear Ms. Gossett:

We have reviewed your ~~Section 510(k) notification of intent to market the device referenced~~ above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to ~~legally marketed predicate devices marketed in interstate commerce~~ prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The ~~general controls provisions of the Act~~ include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or ~~class III~~ (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, ~~Parts 800 to 895~~.


A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

Page 2

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "<http://www.fda.gov/cdrh/dsma/dsmamain.html>".

Sincerely yours,



Steven I. Gutman, M.D., M.B.A.

Director

Division of Clinical Laboratory Devices

Office of Device Evaluation

Center for Devices and Radiological Health

Enclosure


INDICATIONS FOR USE STATEMENT

510(k) Number: K002930

Device Name: Instacult™

Indications for Use:

The Instacult™ is a guaiac-based test for the qualitative detection occult blood in stool, which may be indicative of gastrointestinal disease. The test is provided by physicians and hospitals to patients for stool specimen retrieval. The tests containing the stool specimens are returned to the physician or hospital for analysis. Instacult™ is useful as an aid in the diagnosis of a number of gastrointestinal disorders. When used for colorectal cancer screening programs, The American Cancer Society recommends testing of at least three consecutive bowel movements due to the irregularity of bleeding from lesions in the intestinal tract.


(Division Sign-Off)
Division of Clinical Laboratory Devices
510(k) Number K002930

Rescaphis ✓